Literature DB >> 18495779

In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject.

Athe M N Tsibris1, Manish Sagar, Roy M Gulick, Zhaohui Su, Michael Hughes, Wayne Greaves, Mani Subramanian, Charles Flexner, Françoise Giguel, Kay E Leopold, Eoin Coakley, Daniel R Kuritzkes.   

Abstract

Little is known about the in vivo development of resistance to human immunodeficiency virus type 1 (HIV-1) CCR5 antagonists. We studied 29 subjects with virologic failure from a phase IIb study of the CCR5 antagonist vicriviroc (VCV) and identified one individual with HIV-1 subtype C who developed VCV resistance. Studies with chimeric envelopes demonstrated that changes within the V3 loop were sufficient to confer VCV resistance. Resistant virus showed VCV-enhanced replication, cross-resistance to another CCR5 antagonist, TAK779, and increased sensitivity to aminooxypentane-RANTES and the CCR5 monoclonal antibody HGS004. Pretreatment V3 loop sequences reemerged following VCV discontinuation, implying that VCV resistance has associated fitness costs.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18495779      PMCID： PMC2519584          DOI： 10.1128/JVI.00444-08

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  20 in total

1.  Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism.

Authors:  Jeannette M Whitcomb; Wei Huang; Signe Fransen; Kay Limoli; Jonathan Toma; Terri Wrin; Colombe Chappey; Linda D B Kiss; Ellen E Paxinos; Christos J Petropoulos
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

2.  Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant.

Authors:  Xueling Wu; Adam B Parast; Barbra A Richardson; Ruth Nduati; Grace John-Stewart; Dorothy Mbori-Ngacha; Stephanie M J Rainwater; Julie Overbaugh
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

3.  Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir.

Authors:  Mike Westby; Marilyn Lewis; Jeannette Whitcomb; Mike Youle; Anton L Pozniak; Ian T James; Tim M Jenkins; Manos Perros; Elna van der Ryst
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

4.  Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.

Authors:  Mike Westby; Caroline Smith-Burchnell; Julie Mori; Marilyn Lewis; Michael Mosley; Mark Stockdale; Patrick Dorr; Giuseppe Ciaramella; Manos Perros
Journal:  J Virol       Date:  2006-12-20       Impact factor: 5.103

5.  Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).

Authors:  Andre J Marozsan; Shawn E Kuhmann; Thomas Morgan; Carolina Herrera; Enid Rivera-Troche; Serena Xu; Bahige M Baroudy; Julie Strizki; John P Moore
Journal:  Virology       Date:  2005-07-20       Impact factor: 3.616

6.  HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry.

Authors:  Pavel Pugach; Andre J Marozsan; Thomas J Ketas; Elissa L Landes; John P Moore; Shawn E Kuhmann
Journal:  Virology       Date:  2006-12-12       Impact factor: 3.616

7.  The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor.

Authors:  Christian Watson; Stephen Jenkinson; Wieslaw Kazmierski; Terry Kenakin
Journal:  Mol Pharmacol       Date:  2005-01-11       Impact factor: 4.436

8.  Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.

Authors:  Roy M Gulick; Zhaohui Su; Charles Flexner; Michael D Hughes; Paul R Skolnik; Timothy J Wilkin; Robert Gross; Amy Krambrink; Eoin Coakley; Wayne L Greaves; Andrew Zolopa; Richard Reichman; Catherine Godfrey; Martin Hirsch; Daniel R Kuritzkes
Journal:  J Infect Dis       Date:  2007-06-05       Impact factor: 5.226

9.  Development of a yeast-based recombination cloning/system for the analysis of gene products from diverse human immunodeficiency virus type 1 isolates.

Authors:  Andre J Marozsan; Eric J Arts
Journal:  J Virol Methods       Date:  2003-08       Impact factor: 2.014

10.  Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor.

Authors:  Shawn E Kuhmann; Pavel Pugach; Kevin J Kunstman; Joann Taylor; Robyn L Stanfield; Amy Snyder; Julie M Strizki; Janice Riley; Bahige M Baroudy; Ian A Wilson; Bette T Korber; Steven M Wolinsky; John P Moore
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103
View more
  63 in total

1.  Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists.

Authors:  Timothy J Henrich; Nicolas R P Lewine; Sun-Hee Lee; Suhas S P Rao; Reem Berro; Roy M Gulick; John P Moore; Athe M N Tsibris; Daniel R Kuritzkes
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

2.  Sensitivity changes over the course of infection increases the likelihood of resistance against fusion but not CCR5 receptor blockers.

Authors:  Nikolaos Chatziandreou; Ana Belen Arauz; Ines Freitas; Phyu Hninn Nyein; Gregory Fenton; Shruti H Mehta; Gregory D Kirk; Manish Sagar
Journal:  AIDS Res Hum Retroviruses       Date:  2012-06-25       Impact factor: 2.205

3.  HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells.

Authors:  Jennifer M Pfaff; Craig B Wilen; Jessamina E Harrison; James F Demarest; Benhur Lee; Robert W Doms; John C Tilton
Journal:  J Virol       Date:  2010-04-21       Impact factor: 5.103

4.  Short communication: antiretroviral therapy resistance mutations present in the HIV type 1 subtype C pol and env regions from therapy-naive patients in Zambia.

Authors:  Sandra Gonzalez; Clement Gondwe; Damien C Tully; Veenu Minhas; Danielle Shea; Chipepo Kankasa; Tendai M'soka; Charles Wood
Journal:  AIDS Res Hum Retroviruses       Date:  2010-07       Impact factor: 2.205

5.  Primary infection by a human immunodeficiency virus with atypical coreceptor tropism.

Authors:  Chunlai Jiang; Nicholas F Parrish; Craig B Wilen; Hui Li; Yue Chen; Jeffrey W Pavlicek; Anna Berg; Xiaozhi Lu; Hongshuo Song; John C Tilton; Jennifer M Pfaff; Elizabeth A Henning; Julie M Decker; M Anthony Moody; Mark S Drinker; Robert Schutte; Stephanie Freel; Georgia D Tomaras; Rebecca Nedellec; Donald E Mosier; Barton F Haynes; George M Shaw; Beatrice H Hahn; Robert W Doms; Feng Gao
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

6.  Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab.

Authors:  Jonathan Toma; Steven P Weinheimer; Eric Stawiski; Jeannette M Whitcomb; Stanley T Lewis; Christos J Petropoulos; Wei Huang
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

7.  HIV-1 drug-resistant minority variants: sweating the small stuff.

Authors:  Jonathan Z Li
Journal:  J Infect Dis       Date:  2013-11-23       Impact factor: 5.226

8.  Analysis of primary resistance mutations to HIV-1 entry inhibitors in therapy naive subtype C HIV-1 infected mother-infant pairs from Zambia.

Authors:  Hongyan Guo; Chang Liu; Bin Liu; Charles Wood; Xiaohong Kong
Journal:  J Clin Virol       Date:  2013-06-25       Impact factor: 3.168

9.  Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1.

Authors:  Alonso Heredia; Olga Latinovic; Robert C Gallo; Gregory Melikyan; Marv Reitz; Nhut Le; Robert R Redfield
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

10.  Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc.

Authors:  Robert A Ogert; Lei Ba; Yan Hou; Catherine Buontempo; Ping Qiu; Jose Duca; Nicholas Murgolo; Peter Buontempo; Robert Ralston; John A Howe
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.